Company Overview of University of Wisconsin - Madison
The University of Wisconsin – Madison is an educational and research institution. Its schools and colleges offer graduate, post graduate, doctoral, research, and special academic programs. Its undergraduate and graduate courses include programs in the arts, sciences, engineering, medicine, business, and humanities. The University of Wisconsin – Madison was founded in 1848 and is based in Madison, Wisconsin. The university has endowment assets worth $1.12 billion.
161 Bascom Hall
500 Lincoln Drive
Madison, WI 53706
Founded in 1848
Key Executives for University of Wisconsin - Madison
Vice Chancellor for Administration
Dean of Graduate School and Vice Chancellor for Research
Director of Auxiliary Operations Analysis
Director of the Wisconsin Center for Dairy Research
Dean of the College of Letters and Science
Compensation as of Fiscal Year 2016.
University of Wisconsin - Madison Key Developments
University of Wisconsin - Madison Appoints Matt Kussow -as the First Executive Director
Aug 24 16
University of Wisconsin-Madison hired Matt Kussow - who recently lobbied for UW in the state capitol - as the first executive director for the group called Badger Advocates. Badger Advocates wants to take a broader, independent view of the major, strategic issues that affect the university. Matt brings experiences from both the capitol and the campus which will help ensure the success of this initiative. Nettles, an attorney and managing director of Generation Growth Capital in Milwaukee, chaired the search committee for an executive director. He declined to identify Badger Advocates' board members but said a list will be released in the next week or so.
University of Wisconsin - Madison Wins $5,138,405 Federal Contract
Jun 2 16
University of Wisconsin-Madison won a $5,138,405 federal contract from the U.S. Department of Health and Human Services' National Institutes of Health for non-human primate major histo-compatibility complex allele discovery and typing technology development.
Morphotek, Inc. Announces Collaboration Agreement with University of Wisconsin-Madison
Dec 3 15
Morphotek Inc., a subsidiary of Eisai Inc. announced that it entered into a collaborative research agreement with University of Wisconsin-Madison to elucidate the immunosuppressive effects of the CA125 tumor antigen on the investigational monoclonal antibody farletuzumab. Farletuzumab is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha (FRA), a cell-surface protein highly expressed in ovarian carcinoma but largely absent from normal tissue. The collaboration will initially investigate the immune status of primary macrophage and NK cells derived from the blood of ovarian cancer patients with varying levels of CA125. In addition, the collaboration will test whether the farletuzumab-mediated killing of ovarian cancer cells using patient-derived immune cells is affected by tumor-derived CA125.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries